Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure

Abstract

Purpose of review Hepatitis C (HCV) is the most common cause of viral hepatitis in elderly individuals. This patient population previously experienced suboptimal outcomes with interferon-based regimens. Unfortunately, patients aged 65 years and older were underrepresented in phase 2 and 3 clinical trials with newer direct acting antiviral (DAA) therapies. Since the advent of second-generation DAA in 2013, numerous robust real-world experiences highlighting the efficacy and safety of DAA in the elderly have been published. This review article summarizes the cascade of care for hepatitis C from diagnosis to cure from an evidence-based perspective of the aging population. Recent finding In a large study from the Veterans Affairs Healthcare System, the overall sustained virologic response (SVR) of 15,884 patients treated with DAA regimens was 91.2%. These newer therapies remained highly effective in the subset of patients aged 65 years and older with SVR rates above 90%. A Spanish National Registry reported outcomes in patients ≥ 65 years old treated for HCV with oral DAA regimens over a 2-year period. The overall SVR was 94% in the study of 1252 subjects. Summary Current real-world data imply DAA treatment regimens remain highly effective and safe in elderly patients when compared to the general population.

Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: A nationwide cross-sectional study

“…In a previous study including nationwide Korean CHC patients, the mean age was around 57. This suggests an aging trend in Korean patients with HCV wherein, risk factors associated with aging should be taken into consideration when treating CHC patients of older age [17].…”

Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea

“…Generally, our findings are consistent with the observation that fibrosis may not compromise SOF/VEL and SOF/DCV efficacy, but decompensated cirrhosis may undermine SVR 28 . To illustrate these points, Abdul and colleagues noted a significant difference in treatment outcomes between patients with disparate Child-Turcotte-Pugh (CTP) classification (95.5% in CTP A vs. 90.8% in CTP B, p value = 0.010) 29 . Literature also suggests that specific HCV genotypes (e.g., HCV-GT4 subtype 4k, 4q, 4p, and 4r) and the emergence of resistance-associated mutations (RAM) 30 may contribute to virological failure.…”